From: Effect of relaxation therapy on benzodiazepine use in patients with medically unexplained symptoms
Independent Variables | Comparison | Crude analysis | Adjusted analysisa | Adjusted analysisb | |||
---|---|---|---|---|---|---|---|
OR (95% CI) | P value | OR (95% CI) | P value | OR (95% CI) | P value | ||
Dose used | DAP d120 mg/month increase | 0.48 (0.13–1.79) | 0.27 | 0.45 (0.11–1.78) | 0.25 | 0.25 (0.04–1.62) | 0.15 |
Duration since use | ≦6 months vs 6 months< | 0.06 (0.01–0.36) | < 0.01 | 0.04 (0.01–0.29) | < 0.01 | 0.04 (0.01–0.37) | < 0.01 |
Concomitant use of antidepressants | Yes vs no | 1.66 (0.31–9.05) | 0.56 | 1.26 (0.18–8.88) | 0.81 | 2.32 (0.20–26.10) | 0.49 |
Use of short-acting BZDc | Yes vs no | 2.54 (0.41–15.90) | 0.32 | 2.53 (0.38–16.60) | 0.33 | 5.05 (0.48–53.10) | 0.18 |